Reliance Genemedix withdraws European biosimilar EPO marketing application
This article was originally published in Scrip
Reliance GeneMedix has withdrawn its application for marketing authorisation approval through the centralised procedure for its biosimilar Epostim (erythropoietin). The firm said in a statement that it had been unable to comply with a request from the European Medicines Agency for more information in the permitted time frame.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.